1 reports of this reaction
16.7% of all THUJA OCCIDENTALIS LEAFY TWIG reports
#1 most reported adverse reaction
AGRANULOCYTOSIS is the #1 most commonly reported adverse reaction for THUJA OCCIDENTALIS LEAFY TWIG, manufactured by BM Private Limited. There are 1 FDA adverse event reports linking THUJA OCCIDENTALIS LEAFY TWIG to AGRANULOCYTOSIS. This represents approximately 16.7% of all 6 adverse event reports for this drug.
Patients taking THUJA OCCIDENTALIS LEAFY TWIG who experience agranulocytosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AGRANULOCYTOSIS is a frequently reported adverse event for THUJA OCCIDENTALIS LEAFY TWIG, accounting for a significant proportion of all reports.
In addition to agranulocytosis, the following adverse reactions have been reported for THUJA OCCIDENTALIS LEAFY TWIG:
The following drugs have also been linked to agranulocytosis in FDA adverse event reports:
AGRANULOCYTOSIS has been reported as an adverse event in 1 FDA reports for THUJA OCCIDENTALIS LEAFY TWIG. This does not prove causation, but indicates an association observed in post-market surveillance data.
AGRANULOCYTOSIS accounts for approximately 16.7% of all adverse event reports for THUJA OCCIDENTALIS LEAFY TWIG, making it one of the most commonly reported side effect.
If you experience agranulocytosis while taking THUJA OCCIDENTALIS LEAFY TWIG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.